Clinical trials: Active Juvenile Psoriatic Arthritis
Arthritis, Juvenile
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
- Trial name
- PSUMMIT-Jr (NCT05083182)
- Testing
- Ustekinumab, Guselkumab
- Where
- 50 sites in United States, Argentina and 8 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
Active Juvenile Psoriatic Arthritis
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
- Trial name
- PEAPOD (NCT04804553)
- Testing
- Apremilast
- Where
- 44 sites in Belgium, France and 12 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Juvenile Psoriatic Arthritis
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
- Trial name
- NCT06869551
- Testing
- Deucravacitinib
- Where
- 48 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
- Trial name
- NCT06668181
- Testing
- Bimekizumab
- Where
- 23 sites in Canada, France and 4 more
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL
Arthritis, Rheumatoid, Spondylitis, Ankylosing
C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France
C.O.R.P.U.S. is the first French observatory of care practices in active inflammatory rheumatism of children and adults: rheumatoid arthritis, spondylarthropathy, and idiopathic juvenile arthritis, established under the auspices…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Arthitis, Juvenile Idiopathic
- Trial name
- NCT02886689
- Testing
- TNF-alpha antagonist and other biotherapy
- Where
- France
- Volunteers
- 5,400 people
- Sponsor
- Central Hospital, Nancy, France
Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness.
- Trial name
- KRXeljanzJIA (NCT05754710)
- Testing
- Xeljanz
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Pfizer
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Pediatric Arthritis Study of Certolizumab Pegol
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
- Trial name
- PASCAL (NCT01550003)
- Testing
- Certolizumab Pegol (CZP)
- Where
- 36 sites in United States, Argentina and 5 more
- Volunteers
- 193 people
- Sponsor
- UCB BIOSCIENCES GmbH
Juvenile Idiopathic Arthritis
Prospective Observational Study to Evaluate Secukinumab Treatment Effectiveness in Pediatric Patients With Active Juvenile Enthesitis-related or Psoriatic Arthritis
This is a multicenter, non-interventional, cohort study in pediatric patients with active juvenile enthesitis-related or psoriatic arthritis
- Trial name
- Toddler (NCT06431750)
- Testing
- Secukinumab
- Sponsor
- Novartis Pharmaceuticals